1. Scrip
  2. >>Business

Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug

Provention’s Therapy Delays Onset By Three Years

 
• By Andrew McConaghie

Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.

Sanofi logo
Sanofi has exited Type 1 diabetes research, but retains a large commercial infrastructure in the US and worldwide. • Source: Shutterstock

Sanofi has entered into an alliance with Provention Bio for the US commercialization of teplizumab, a potential gamechanger in the field of type 1 diabetes which has shown in studies it can delay onset of the disease by three years.

The deal is an interesting development for Sanofi, which in recent years has de-prioritized its former blockbuster insulin brands

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.